NYSE:AZN - AstraZeneca Stock Price, Forecast & News

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

AstraZeneca announced a semiannual dividend on Friday, February 15th. Shareholders of record on Friday, March 1st will be given a dividend of $0.95 per share on Wednesday, March 27th. This represents a yield of 4.64%. The ex-dividend date of this dividend is Thursday, February 28th. This is an increase from AstraZeneca's previous semiannual dividend of $0.45. View AstraZeneca's Dividend History.

AstraZeneca shares split on the morning of Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were issued to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

AstraZeneca plc (NYSE:AZN) released its quarterly earnings data on Thursday, October, 24th. The company reported $0.50 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.05. The company had revenue of $6.13 billion for the quarter, compared to analysts' expectations of $6.07 billion. AstraZeneca had a net margin of 8.42% and a return on equity of 38.63%. The firm's quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.71 earnings per share. View AstraZeneca's Earnings History.

AstraZeneca is scheduled to release their next quarterly earnings announcement on Friday, February 14th 2020. View Earnings Estimates for AstraZeneca.

AstraZeneca updated its FY19 earnings guidance on Thursday, October, 24th. The company provided earnings per share guidance of $3.50-3.70 for the period, compared to the Thomson Reuters consensus estimate of $3.62.

14 Wall Street analysts have issued 12 month price targets for AstraZeneca's stock. Their forecasts range from $40.73 to $57.00. On average, they expect AstraZeneca's share price to reach $50.68 in the next year. This suggests that the stock has a possible downside of 1.3%. View Analyst Price Targets for AstraZeneca.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 4 sell ratings, 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AstraZeneca.

News coverage about AZN stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. AstraZeneca earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for AstraZeneca.

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Bayer (BAYRY) and Celgene (CELG).

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), AT&T (T), AbbVie (ABBV), Bank of America (BAC), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), Micron Technology (MU), Gilead Sciences (GILD), Intel (INTC) and Netflix (NFLX).

AstraZeneca's stock is owned by a number of of retail and institutional investors. Top institutional investors include Galibier Capital Management Ltd. (0.01%), Vigilant Capital Management LLC (0.01%), Park National Corp OH (0.01%), Patten Group Inc. (0.00%), AE Wealth Management LLC (0.00%) and Archford Capital Strategies LLC (0.00%). View Institutional Ownership Trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including United Services Automobile Association, Clean Yield Group, TIAA FSB, Archford Capital Strategies LLC, Raymond James Trust N.A., Gradient Investments LLC, Vigilant Capital Management LLC and Nisa Investment Advisors LLC. View Insider Buying and Selling for AstraZeneca.

AZN stock was bought by a variety of institutional investors in the last quarter, including Galibier Capital Management Ltd., FNY Investment Advisers LLC, AE Wealth Management LLC, Park National Corp OH, We Are One Seven LLC, Huntington National Bank, Steward Partners Investment Advisory LLC and Patten Group Inc.. View Insider Buying and Selling for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $51.33.

AstraZeneca has a market capitalization of $134.68 billion and generates $22.09 billion in revenue each year. The company earns $2.16 billion in net income (profit) each year or $1.73 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.View Additional Information About AstraZeneca.

The official website for AstraZeneca is http://www.astrazeneca.com/.

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]